CAR T therapy for certain GD2 brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor is confirmed to have GD2 in the brain (by lab testing), or you have a specific genetic change (H3K27) when GD2 testing isn’t possible.
- You have a certain type of brain tumor: newly diagnosed or returning/progressing (DMG/HGG, including some pontine cases, or other high-grade CNS tumors listed by the study).
- Your tumor measurements on MRI fit the study size rules (must be under 5 cm, with specific exceptions after radiation).
- MRI must show measurable tumor areas in at least two directions.
- You must be 12 months to 25 years old, and well enough to participate (function score at least 50, or at least 60 for pontine group).
- You must have finished standard radiation at least 4 weeks ago, and be stable (neurologic exam for 7 days; steroids can’t be too high).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This trial tests a new type of immunotherapy called CAR T-cells that are designed to target and kill brain tumor cells that have a specific marker called CD70. It is for children and young adults with certain high-grade brain tumors, either newly diagnosed or that have come back.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This Phase 1 study tests a custom immune therapy called GD2 CAR T cells in children and adults with a specific type of diffuse midline glioma (DMG) that has the H3K27M mutation. The goal is to see if the treatment is safe and can help control the cancer.
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.